Two anti-PD-1 antibodies (nivolumab (BMS-936558/ONO-4538, Opdivo®) and pembrolizumab (Keytruda®)) and three anti-PD-L1 antibodies (durvalumab, atezolizumab, and avelumab) have been approved for the treatment of various types of cancer, including lymphomas [68,91,92,93,94,95,96]. This evidence concerns the gene CD274 and lymphoma.